Dizal Pharma Chairman, Executives Plan to Cut Up to 0.7785% Stake

Dizal Pharmaceutical announced on September 3 that its chairman and chief executive officer, Dr. Zhang Xiaolin, along with Vice President and Chief Medical Officer Dr. Yang Zhenfan, Vice President and Chief Commercial Officer Wu Qingyi, and Vice President Zhang Zhiwei, plan to collectively reduce their holdings by up to 0.7785% of the company's total share capital.

The proposed reduction represents a combined sale of shares not exceeding 0.7785% of the company's outstanding shares, as disclosed in the official announcement.